Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) poses a major therapeutic challenge, with loss of radioiodine avidity, limited treatment options, and worse outcomes. Current risk stratification systems were not designed to predict RAIR transformation before clinical refractoriness. Methods: This retrospective two-center study included a development cohort of 302 consecutive patients and an external validation cohort of 122.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
